Vir Biotechnology Revenue 2018-2021 | VIR

Vir Biotechnology annual/quarterly revenue history and growth rate from 2018 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Vir Biotechnology revenue for the quarter ending June 30, 2021 was $0.177B, a 164.33% increase year-over-year.
  • Vir Biotechnology revenue for the twelve months ending June 30, 2021 was $0.183B, a 143.32% increase year-over-year.
  • Vir Biotechnology annual revenue for 2020 was $0.076B, a 843.86% increase from 2019.
  • Vir Biotechnology annual revenue for 2019 was $0.008B, a 24.16% decline from 2018.
  • Vir Biotechnology annual revenue for 2018 was $0.011B, a 293.94% increase from 2017.
Vir Biotechnology Annual Revenue
(Millions of US $)
2020 $76
2019 $8
2018 $11
2017 $3
Vir Biotechnology Quarterly Revenue
(Millions of US $)
2021-06-30 $177
2021-03-31 $2
2020-12-31 $2
2020-09-30 $2
2020-06-30 $67
2020-03-31 $6
2019-12-31 $1
2019-09-30 $1
2019-06-30 $2
2019-03-31 $4
2018-12-31
2018-09-30 $3
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.723B $0.076B
Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29